Print

Semafore Pharmaceuticals, Inc. Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 American Association for Cancer Research Annual Meeting  
3/9/2011 9:24:15 AM

INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR), to be held April 2-6, 2011, in Orlando, FL. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of all Class I phosphatidylinositol 3-kinase (PI3K) isoforms, mammalian target of rapamycin (mTOR), the proto-oncogene PIM-1, and other cancer-specific kinase targets.
//-->